Sign in to view content

Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD

Peter A. Campochiaro, MD

Video
Published 2020

Related

Treatment course and outcomes of neovascular age-related macular degeneration in patients receiving intraocular pressure-lowering drops
Bobeck S Modjtahedi, MD
On Demand Cases, Courses, and Papers
2019
Episode 15: Serum VEGF Levels in the IVAN Trial with Dr. Usha Chakravarthy
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
Brolucizumab: Will it Make a Differance
Andrew P. Schachat, MD
Updates from the Field
2018

Category: AMD-Neovascular

See more